Pharmacia Trelstar LA
Executive Summary
Three-month controlled-release formulation of triptorelin is approved by FDA June 29 for palliative treatment of advanced prostate cancer. Pharmacia will launch Trelstar LA together with Trelstar Depot, a one-month formulation approved for the same indication on June 15, 2000. Pharmacia licensed North American rights to the luteinizing hormone releasing hormone agonist from Swiss drug developer Debiopharm. FDA deemed Trelstar Depot "not-approvable" for endometriosis